How to take Ritlecitinib

Ritlecitinib (Ritlecitinib) is used to treat severe alopecia areata (AA) in adults and adolescents 12 years and older. Ritexitinib is a kinase inhibitor. It is not recommended to use ritexitinib in combination with otherJAK inhibitors, biological immunomodulators, cyclosporine or other potent immunosuppressants. Ritlecitinib is contraindicated in patients with known hypersensitivity to Ritlecitinib or any of its excipients.

Absolute lymph count (ALC) and platelet count before and after initiation of ritixitinib treatment 4 weeks and thereafter according to routine patient management; for patients with latent tuberculosis or patients at high risk for tuberculosis with a negative latent tuberculosis test, initiate prophylactic treatment for latent tuberculosis before starting ritixitinib. The recommended dose of ritexitinib is 50 mg once daily, with or without food. If a dose is accidentally missed, the dose should be taken as soon as possible, unless less than 8 hours before the next dose, in which case the missed dose should be skipped. Thereafter, resume dosing at regularly scheduled times.

If treatment interruption with ritexitinib is necessary, temporary treatment interruptions of less than6 weeks are not expected to result in a significant reduction in regenerated scalp hair. Treatment should be discontinued if platelet count is <50,000/mm, ALC, or <500/mm. Rituxitinib is not recommended for patients with hepatitis B or C. Ritexitinib is not recommended for patients with severe hepatic impairment (ChildPugh class C). Since ritexitinib is a new drug for the treatment of alopecia areata, it has not yet been marketed in China and has not been included in medical insurance. Its price has not yet been learned. For specific prices and drug details, please consult the medical consultant of Yaode.